Endocyte (ECYT) Given Consensus Recommendation of “Buy” by Brokerages
Shares of Endocyte (NASDAQ:ECYT) have earned an average recommendation of “Buy” from the seven brokerages that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $7.00.
A number of brokerages have commented on ECYT. Jefferies Group began coverage on Endocyte in a research report on Friday, April 13th. They issued a “buy” rating on the stock. BidaskClub lowered Endocyte from a “strong-buy” rating to a “buy” rating in a research report on Thursday. ValuEngine upgraded Endocyte from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Wells Fargo began coverage on Endocyte in a research report on Friday, March 9th. They issued an “outperform” rating on the stock. Finally, Cowen upgraded Endocyte from a “market perform” rating to an “outperform” rating in a research report on Tuesday, February 27th.
In other news, VP Christopher P. Leamon sold 5,036 shares of the firm’s stock in a transaction on Friday, March 9th. The stock was sold at an average price of $9.07, for a total value of $45,676.52. Following the transaction, the vice president now directly owns 143,470 shares in the company, valued at approximately $1,301,272.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 14.86% of the stock is owned by company insiders.
Shares of ECYT opened at $9.40 on Friday. The firm has a market capitalization of $622.79, a price-to-earnings ratio of -9.40 and a beta of 0.48. Endocyte has a 52 week low of $1.17 and a 52 week high of $11.54.
Endocyte (NASDAQ:ECYT) last announced its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.18) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.02). The firm had revenue of $0.01 million during the quarter. Endocyte had a negative net margin of 78,662.86% and a negative return on equity of 40.33%. The business’s revenue was up .0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.26) EPS. equities research analysts predict that Endocyte will post -0.76 earnings per share for the current fiscal year.
Endocyte Company Profile
Endocyte, Inc, a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer.
Receive News & Ratings for Endocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte and related companies with MarketBeat.com's FREE daily email newsletter.